Sweden's Spago Nanomedical Q1 loss narrows

Spago Nanomedical AB (publ)

07/05/2026 07:11

Overview

Sweden cancer therapy developer's Q1 net sales fell sharply yr/yr, net loss narrowed

Company advanced Tumorad clinical trial, meeting a primary endpoint and continuing patient recruitment

Spago Nanomedical strengthened management team as it prepares for next clinical phase

Outlook

Company is preparing for phase II of Tumorad-01 trial and regulatory interactions

Spago Nanomedical says securing financing for phase IIa remains a clear priority

Company notes growing interest in radiopharmaceuticals from potential partners

Result Drivers

CLINICAL TRIAL PROGRESS - Company said Tumorad-01 trial met a primary endpoint and continues to recruit patients, supporting further clinical development

PROOF-OF-CONCEPT DATA - Company reported visible tumor uptake of 177Lu-SN201 in additional patients, strengthening proof-of-concept for Tumorad

ORGANIZATIONAL PREPARATION - Spago Nanomedical strengthened its management team to support upcoming clinical and manufacturing activities

Company press release: ID:nMFN18xV9Y

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
SEK 22,000
Q1 Adjusted EPS
-SEK 0.01
Q1 Net Income
-SEK 6.80 mln
Q1 Operating Expenses
-SEK 7.97 mln


Analyst Coverage

Wall Street's median 12-month price target for Spago Nanomedical AB (publ) is SEK0.24, about 108.7% above its May 6 closing price of SEK0.12

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)